In this segment, Dr. Gregory Vidal explains why it is essential for patients to understand their hormone receptor status and ...
For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...
persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...
Effect of timing of recurrence on outcomes in patients with metastatic breast cancer treated with CDK4/6 inhibitors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Human epidermal growth factor receptor 2 (HER2) proteins are found on the surface of breast cells and are involved in normal cell growth. Too much HER2 protein, however, can cause some types of breast ...
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 This open-label, parallel-group trial ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
Postmenopausal obesity increases ER-positive breast cancer risk, particularly in non-HRT users, while premenopausal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results